T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Parker-Hannifin
PH
$135B
| $2.36B | 0.25% |
2,685,757
-159,242
| -6% | -$130M |
|
|
77
Lam Research
LRCX
$408B
| $2.34B | 0.25% |
13,695,210
+10,666,540
| +352% | +$1.66B |
|
78
Philip Morris
PM
$290B
| $2.27B | 0.24% |
14,161,027
+1,569,685
| +12% | +$243M |
|
79
Cisco
CSCO
$488B
| $2.26B | 0.24% |
29,289,151
+14,874,407
| +103% | +$1.1B |
|
80
Spotify
SPOT
$101B
| $2.25B | 0.24% |
3,869,472
+149,479
| +4% | +$93.4M |
|
81
AbbVie
ABBV
$440B
| $2.25B | 0.24% |
9,826,388
-775,839
| -7% | -$177M |
|
82
Old Dominion Freight Line
ODFL
$44.1B
| $2.23B | 0.24% |
14,223,960
+1,761,511
| +14% | +$253M |
|
83
Ameren
AEE
$30.1B
| $2.18B | 0.23% |
21,789,822
-6,853,394
| -24% | -$703M |
|
84
Chipotle Mexican Grill
CMG
$41.3B
| $2.16B | 0.23% |
58,447,867
+9,237,720
| +19% | +$334M |
|
85
Salesforce
CRM
$158B
| $2.08B | 0.22% |
7,839,178
+582,314
| +8% | +$145M |
|
86
SLB Ltd
SLB
$78.1B
| $2.07B | 0.22% |
53,951,531
-5,490,903
| -9% | -$199M |
|
87
Mondelez International
MDLZ
$79.4B
| $2.01B | 0.22% |
37,366,588
+3,993,811
| +12% | +$230M |
|
88
CrowdStrike
CRWD
$226B
| $2B | 0.22% |
17,086,764
+215,252
| +1% | +$27.4M |
|
89
Coca-Cola
KO
$373B
| $1.98B | 0.21% |
28,297,734
-1,669,243
| -6% | -$116M |
|
90
Merck
MRK
$328B
| $1.97B | 0.21% |
18,753,390
+5,152,069
| +38% | +$484M |
|
91
Datadog
DDOG
$86.5B
| $1.96B | 0.21% |
14,423,814
+956,993
| +7% | +$151M |
|
92
CME Group
CME
$94.3B
| $1.88B | 0.2% |
6,886,521
-474,687
| -6% | -$129M |
|
93
Xcel Energy
XEL
$49.1B
| $1.86B | 0.2% |
25,127,230
-2,795,545
| -10% | -$220M |
|
94
Qualcomm
QCOM
$171B
| $1.86B | 0.2% |
10,844,836
+64,450
| +0.6% | +$11M |
|
95
Abbott
ABT
$192B
| $1.84B | 0.2% |
14,719,154
-1,081,605
| -7% | -$138M |
|
96
Fabrinet
FN
$20.5B
| $1.84B | 0.2% |
4,041,227
+2,504,841
| +163% | +$1.09B |
|
97
HubSpot
HUBS
$10.5B
| $1.84B | 0.2% |
4,581,922
+1,224,424
| +36% | +$507M |
|
98
Intel
INTC
$509B
| $1.77B | 0.19% |
48,007,417
+3,832,960
| +9% | +$145M |
|
99
Wells Fargo
WFC
$269B
| $1.74B | 0.19% |
18,630,067
-4,072,910
| -18% | -$354M |
|
100
Cigna
CI
$73.3B
| $1.73B | 0.19% |
6,270,213
-5,032,153
| -45% | -$1.41B |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.